SR-9011 REV-ERB Agonist Research Overview
What Is SR-9011?
SR-9011 is a synthetic small-molecule research compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ.
These receptors are also known as nuclear receptor subfamily 1 group D member 1 and member 2, abbreviated as NR1D1 and NR1D2.
SR-9011 is commonly included within commercial SARMs collections because it is searched alongside compounds such as S-4 Andarine, S-23, RAD-140 and LGD-4033. However, SR-9011 is not scientifically classified as a selective androgen receptor modulator.
Its principal research targets are REV-ERBα and REV-ERBβ—not the androgen receptor.
This distinction is essential when discussing SR-9011 research, comparing compounds or selecting suitable experimental endpoints.
The principal molecular characteristics of SR-9011 include:
Compound name—SR-9011, Alternative forms—SR9011 and SR 9011, Research classification—Synthetic REV-ERB agonist, Molecular formula—C₂₃H₃₁ClN₄O₃S, Approximate molecular weight—479.04 g/mol, CAS number—1379686-29-9, Principal research targets—REV-ERBα and REV-ERBβ.
Researchers searching for SR-9011 UK, SR-9011 for sale UK, buy SR-9011 UK or where to buy SR-9011 should understand this mechanistic classification.
SR-9011 is investigated through circadian, transcriptional and metabolic pathways. It should not be presented as though it directly activates androgen-receptor signalling or shares the same molecular mechanism as genuine SARMs.
This SR-9011 research overview examines its REV-ERB targets, circadian-clock connections, transcriptional-repression mechanisms, principal laboratory applications, analytical identity and current evidence limitations.
Why SR-9011 Is Not a Genuine SARM
SARM stands for selective androgen receptor modulator.
Genuine SARMs interact with the androgen receptor and influence androgen-responsive transcription. Examples include S-4 Andarine, S-23, Ostarine MK-2866, LGD-4033 Ligandrol and RAD-140 Testolone.
SR-9011 does not principally operate through this receptor system.
It is more accurately classified as a REV-ERB agonist.
REV-ERBα and REV-ERBβ are nuclear receptors involved in circadian-clock regulation, metabolism, cellular energy, inflammatory signalling and transcriptional repression.
SR-9011 therefore belongs to a different mechanistic research category.
The principal distinction is:
Genuine SARMs ⟶ Androgen-receptor modulation
SR-9011 ⟶ REV-ERBα and REV-ERBβ activation
SR-9011 is listed within the BioPlex SARMs collection because researchers commonly search for it alongside SARMs and related capsule-based research compounds.
Commercial category placement should not be confused with scientific classification.
Explaining this difference allows BioPlex to capture searches such as SR-9011 SARM and buy SARMs UK while providing more accurate information than websites that describe every product within the category as an androgen-receptor modulator.
How SR-9011 Works in Research
REV-ERBα and REV-ERBβ are ligand-regulated transcription factors associated with the molecular circadian clock.
Unlike many nuclear receptors that activate gene transcription after ligand binding, REV-ERB receptors principally function as transcriptional repressors.
They can interact with specific DNA response elements and recruit co-repressor complexes. These regulatory complexes can reduce transcription of selected genes involved in circadian and metabolic pathways.
The proposed research sequence includes:
SR-9011 interaction with REV-ERB receptors, Stabilisation or enhancement of receptor-associated repression, Recruitment of transcriptional co-repressor machinery, Reduced transcription at selected response elements, Changes in circadian and metabolic gene-expression patterns.
This model provides a framework for designing SR-9011 experiments, but pathway claims should remain qualified.
A change in clock-gene expression after SR-9011 exposure can support REV-ERB-associated activity. It does not independently prove that every observed response results exclusively from REV-ERB activation.
Researchers may use receptor-deficient controls, competing ligands, reporter assays and independent transcriptional measurements to investigate target dependence.
SR-9011 and the Circadian Clock
The circadian clock is a coordinated molecular system that produces approximately 24-hour rhythms in gene expression and biological activity.
Core clock components include CLOCK, BMAL1, PER, CRY, REV-ERB and ROR proteins. These components form interconnected transcriptional feedback loops.
CLOCK and BMAL1 promote transcription of selected clock-associated genes. PER and CRY proteins participate in negative-feedback regulation. REV-ERB receptors contribute additional control by repressing genes including BMAL1 under suitable conditions.
This creates a rhythmic network rather than a simple on-and-off switch.
Circadian variables examined in SR-9011 research may include:
BMAL1 expression, CLOCK-associated transcription, PER and CRY expression, REV-ERBα and REV-ERBβ activity, Rhythm amplitude, Rhythm phase, Period length, Time-dependent transcription, Sleep-and-wake measurements, Activity patterns.
Timing is particularly important in circadian research.
An experimental response may vary according to when SR-9011 is introduced relative to the model’s light–dark cycle, feeding schedule or synchronisation procedure.
Cellular circadian models may be synchronised using serum shock, temperature cycles or chemical methods before SR-9011 exposure.
Researchers should record the experimental time or zeitgeber time associated with each measurement. Combining samples collected at different circadian phases can obscure rhythmic changes.
What Researchers Study SR-9011 For
SR-9011 has been investigated across several connected laboratory and preclinical research areas.
Principal SR-9011 research areas include:
Circadian-clock regulation, REV-ERBα and REV-ERBβ signalling, Transcriptional repression, Metabolic gene expression, Cellular energy regulation, Mitochondrial-associated measurements, Lipid-associated variables, Glucose-associated variables, Sleep architecture, Immune-cell signalling, Inflammatory markers, Cellular proliferation, Autophagy-associated pathways.
These research areas do not establish approved applications. They represent experimental settings in which investigators have used SR-9011 as a molecular tool.
The public evidence is principally cellular and preclinical. Responses can vary considerably according to the cell type, species, exposure period, concentration and experimental timing.
SR-9011 and Metabolic-Signalling Research
REV-ERB receptors connect circadian transcription with metabolic regulation.
Genes involved in lipid handling, glucose-associated pathways, mitochondrial function and energy expenditure can display rhythmic expression. Changing REV-ERB activity may therefore correspond with changes in selected metabolic measurements.
Relevant metabolic endpoints include:
Glucose-associated markers, Lipid-associated measurements, Fatty-acid oxidation, Mitochondrial gene expression, Oxygen-consumption rate, Extracellular acidification, ATP-associated measurements, Cellular energy balance, Body-composition variables, Activity and feeding patterns.
Researchers should distinguish direct cellular metabolic effects from secondary changes caused by altered activity, feeding or circadian timing.
For example, a change in a whole-model metabolic measurement may result from several interacting variables. Cellular assays, pair-feeding controls, activity monitoring and time-matched sampling can help separate these possibilities.
SR-9011 should not be described using guaranteed fat-loss or performance language. It is more accurate to state that it is investigated in metabolic models involving lipid, glucose, mitochondrial and energy-related endpoints.
SR-9011 and Mitochondrial Research
Mitochondria participate in cellular energy generation, substrate oxidation, redox balance and metabolic signalling.
Because REV-ERB receptors influence metabolic transcription, researchers may examine whether SR-9011 exposure corresponds with changes in mitochondrial-associated measurements.
Laboratory measurements may include:
Mitochondrial gene expression, Oxygen-consumption rate, Respiratory capacity, ATP production, Reactive-oxygen-species markers, Mitochondrial membrane potential, Mitochondrial content, Metabolic-enzyme expression.
A change in mitochondrial gene expression does not independently prove improved mitochondrial function.
Researchers should combine transcriptional measurements with functional assays. Oxygen-consumption analysis, ATP measurements and mitochondrial imaging can provide additional information.
Cellular viability should also be measured because reduced cell number or cellular stress can alter metabolic-assay results.
SR-9011 and Sleep-Architecture Research
REV-ERB receptors participate in the regulation of circadian behaviour and sleep-and-wake organisation.
Preclinical research involving synthetic REV-ERB agonists has examined wakefulness, rapid-eye-movement sleep, slow-wave sleep and activity patterns.
The response to SR-9011 may depend on the circadian time at which the compound is introduced.
Relevant measurements include:
Wake duration, Sleep latency, Slow-wave-sleep episodes, Rapid-eye-movement sleep, Locomotor activity, Light–dark timing, Core clock-gene expression, Electroencephalographic measurements.
These findings are model-specific and should not be converted into sleep guidance or personal-use claims.
The principal scientific value lies in demonstrating how pharmacological modulation of clock proteins can alter measurable circadian outputs under controlled conditions.
SR-9011 and Immune-Signalling Research
REV-ERB receptors also participate in the interaction between circadian timing and immune-cell activity.
SR-9011 has been investigated in specialised cellular models involving microglial responses, inflammatory mediators and metabolic changes within immune-associated cells.
Potential research measurements include:
Cytokine expression, Inflammatory transcription, Cellular metabolism, Glucose utilisation, Mitochondrial respiration, Microglial activation markers, Clock-gene expression, Cellular viability.
Inflammatory markers are highly sensitive to experimental context.
Cell type, baseline activation, exposure duration, selected stimulus and circadian phase can all affect the measured response.
A change in one cytokine should not be described as universal immune regulation. Broader marker panels and independent functional assays provide stronger evidence.
SR-9011 and Cellular-Proliferation Research
SR-9011 has also appeared in cellular research involving proliferation, cell-cycle regulation and metabolic vulnerability.
REV-ERB receptors can influence genes associated with metabolism, autophagy and cellular timing. Some experimental systems have examined whether SR-9011 changes the viability or proliferation of selected cell populations.
Researchers may measure:
Cell viability, Cell-cycle distribution, Proliferation rate, Apoptosis-associated markers, Autophagy-associated proteins, Mitochondrial respiration, Gene-expression changes, Metabolic dependency.
These findings must remain model-specific.
A response observed within one specialised cell line does not establish identical activity in other tissues or cellular environments. Concentration-dependent cytotoxicity and solvent effects must also be excluded.
Vehicle controls, non-target cell controls, concentration-response experiments and multiple viability assays are important.
SR-9011 Compared With SR-9009
SR-9011 and SR-9009 are closely related synthetic REV-ERB agonists.
They are frequently compared because both compounds have been used to investigate circadian and metabolic pathways.
They should not be treated as identical.
Relevant comparison points include:
Chemical structure, Molecular formula, Molecular weight, REV-ERBα activity, REV-ERBβ activity, Pharmacokinetics, Cellular exposure, Metabolic stability, Experimental model, Selected concentration.
Both compounds are listed within the wider SARMs market despite not being genuine selective androgen receptor modulators.
A meaningful SR-9011 vs SR-9009 comparison should examine compound-specific evidence rather than assuming that findings obtained with one automatically apply to the other.
Some research has also raised questions about whether all observed effects of synthetic REV-ERB ligands are fully dependent on REV-ERB activity.
This makes receptor-deficient models and independent target-validation methods especially important.
How Researchers Identify and Analyse SR-9011
Accurate analytical identification is necessary because SR-9011 and SR-9009 have similar names, related research applications and comparable molecular weights.
HPLC may be used to evaluate chromatographic purity. Liquid chromatography–mass spectrometry can support molecular-identity analysis. Nuclear magnetic resonance spectroscopy may provide more detailed structural confirmation.
Relevant analytical information includes:
Compound name, Molecular formula, Expected molecular mass, CAS number, Chromatographic purity, Mass-spectrometry identity, Batch number, Capsule strength, Capsule-content uniformity, Storage information.
Purity and identity are not interchangeable.
A dominant chromatographic peak may indicate that one component represents most of the detected material, but additional analysis is necessary to confirm that the component is SR-9011.
Content-uniformity analysis is also relevant for capsule-based research products. It can help establish whether the declared amount is distributed consistently across a production batch.
What Should Researchers Check When Buying SR-9011 in the UK?
Researchers searching for SR-9011 for sale UK, buy SR-9011 UK, SR-9011 capsules UK or where to buy SR-9011 should verify the material’s identity and technical documentation.
Researchers should check:
Correct SR-9011 naming, Classification as a REV-ERB agonist, CAS number 1379686-29-9, Molecular formula C₂₃H₃₁ClN₄O₃S, Approximate molecular weight 479.04 g/mol, Declared capsule strength, Batch information, Purity documentation, Identity testing, Capsule-content consistency, UK manufacturing or encapsulation information, Research-use classification.
The BioPlex SR-9011 REV-ERB agonist research product provides 50 capsules with a declared strength of 15mg per capsule for controlled laboratory and analytical research.
Researchers comparing SARMs for sale UK should recognise that SR-9011 is included within the wider market category but is not a genuine SARM by molecular mechanism.
A technically responsible supplier should explain this distinction rather than implying that SR-9011 activates androgen-receptor pathways.
Limitations of Current SR-9011 Research
SR-9011 has been used in several laboratory and preclinical research areas, but the evidence has important limitations.
Current limitations include:
Heavy reliance on cellular and animal models, Limited controlled clinical evidence, Dependence on experimental timing, Variable concentrations and exposure periods, Questions surrounding target specificity, Potential off-target activity, Differences between SR-9011 and SR-9009, Limited independent pharmacokinetic replication, Differences between characterised research material and commercial products.
Target specificity is particularly important.
An observed response following SR-9011 exposure does not independently prove that the effect was produced exclusively through REV-ERBα or REV-ERBβ.
Researchers should use receptor-deficient models, gene-silencing methods, suitable antagonists, independent agonists and transcriptional assays where possible.
Future research would benefit from stronger target validation, standardised analytical characterisation, complete pharmacokinetic reporting and independent replication across multiple models.
Conclusion
SR-9011 is a synthetic small-molecule REV-ERB agonist investigated in circadian, metabolic, mitochondrial, immune-signalling and cellular-proliferation research.
Its molecular formula is C₂₃H₃₁ClN₄O₃S, its approximate molecular weight is 479.04 g/mol and its CAS number is 1379686-29-9.
SR-9011 is not a genuine selective androgen receptor modulator. It is included within commercial SARMs collections because researchers commonly search for it alongside SARMs and related capsule-based research compounds.
Its principal research targets are REV-ERBα and REV-ERBβ, nuclear receptors involved in transcriptional repression and circadian-clock regulation.
The available evidence supports its use as an experimental molecular tool. However, findings remain principally cellular and preclinical, and not every reported response has been conclusively established as exclusively REV-ERB-dependent.
Researchers considering SR-9011 for sale UK should examine chemical identity, correct classification, capsule strength, batch documentation, chromatographic purity, mass-spectrometry evidence and supplier transparency.
Continue Exploring...
Explore SR-9011 REV-ERB Agonist Research Capsules ⟶
Explore the BioPlex SARMs and Related Research Compounds ⟶
Read the Complete SARMs UK Research Compound Guide ⟶
Read Why MK-677 Ibutamoren Is Not a Genuine SARM ⟶
Learn More About BioPlex Peptides ⟶
All discussion is presented strictly for educational and scientific research purposes only, supporting informed study, data interpretation, and responsible laboratory investigation.
